Full Text Journal Articles by
Author Marc S Sabatine

Advertisement

Find full text journal articles






Cardiovascular Biomarkers and Heart Failure Risk in Stable Patients With Atherothrombotic Disease: A Nested Biomarker Study From TRA 2°P-TIMI 50.

David D Berg, Benjamin L Freedman, Marc P Bonaca, Petr Jarolim, Benjamin M Scirica, Erica L Goodrich, Marc S Sabatine, David A Morrow,

Background Patients with stable atherothrombotic disease vary in their risk of developing heart failure (HF). Circulating cardiovascular biomarkers may improve HF risk assessment and identify patients who may benefit from emerging HF preventive therapies. Methods and Results We measured high-sensitivity cardiac troponin I and BNP (B-type natriuretic peptide) in 15 833 ... Read more >>

J Am Heart Assoc (Journal of the American Heart Association)
[2021, 10(9):e018673]

Cited: 0 times

View full text PDF listing >>



Differentiating Type 1 and Type 2 Myocardial Infarction: Unfortunately, Still More Art Than Science.

Marc S Sabatine,

JAMA Cardiol (JAMA cardiology)
[2021, :]

Cited: 0 times

View full text PDF listing >>



Advertisement

Effect of Dapagliflozin on Cardiovascular Outcomes According to Baseline Kidney Function and Albuminuria Status in Patients With Type 2 Diabetes: A Prespecified Secondary Analysis of a Randomized Clinical Trial.

Thomas A Zelniker, Itamar Raz, Ofri Mosenzon, Jamie P Dwyer, Hiddo H J L Heerspink, Avivit Cahn, Erica L Goodrich, Kyungah Im, Deepak L Bhatt, Lawrence A Leiter, Darren K McGuire, John P H Wilding, Ingrid Gause-Nilsson, Anna Maria Langkilde, Marc S Sabatine, Stephen D Wiviott,

<h4>Importance</h4>Sodium-glucose cotransporter 2 inhibitors, such as dapagliflozin, promote renal glucose excretion and reduce cardiovascular (CV) deaths and hospitalizations for heart failure (HHF) among patients with type 2 diabetes. The relative CV efficacy and safety of dapagliflozin according to baseline kidney function and albuminuria status are unknown.<h4>Objective</h4>To assess the CV efficacy ... Read more >>

JAMA Cardiol (JAMA cardiology)
[2021, :]

Cited: 0 times

View full text PDF listing >>



Dapagliflozin and Recurrent Heart Failure Hospitalizations in Heart Failure with Reduced Ejection Fraction: An Analysis of DAPA-HF.

Pardeep S Jhund, Piotr Ponikowski, Kieran F Docherty, Samvel B Gasparyan, Michael Böhm, Chern-En Chang, Akshay S Desai, Jonathan Howlett, Masafumi Kitakaze, Mark C Petrie, Subodh Verma, Olof Bengtsson, Anna-Maria Langkilde, Mikaela Sjöstrand, Silvio E Inzucchi, Lars Køber, Mikhail N Kosiborod, Felipe A Martinez, Marc S Sabatine, Scott D Solomon, John J V McMurray,

<b>Background:</b> Patients with heart failure and reduced ejection fraction (HFrEF) will experience multiple hospitalizations for heart failure during the course of their disease. We assessed the efficacy of dapagliflozin on reducing the rate of total (i.e. first and repeat) hospitalizations for heart failure in the Dapagliflozin and Prevention of Adverse-outcomes ... Read more >>

Circulation (Circulation)
[2021, :]

Cited: 0 times

View full text PDF listing >>



Plasma Omega-3 Fatty Acids and the Risk of Cardiovascular Events in Patients After an Acute Coronary Syndrome in MERLIN-TIMI 36.

Thomas A Zelniker, David A Morrow, Benjamin M Scirica, Jeremy D Furtado, Jianping Guo, Dariush Mozaffarian, Marc S Sabatine, Michelle L O'Donoghue,

Background Plasma omega-3 polyunsaturated fatty acids (ω3-PUFAs) have been shown to be inversely correlated with the risk of cardiovascular death in primary prevention. The risk relationship in the setting of an acute coronary syndrome is less well established. Methods and Results Baseline plasma ω3-PUFA composition (α-linolenic acid, eicosapentaenoic acid, docosapentaenoic ... Read more >>

J Am Heart Assoc (Journal of the American Heart Association)
[2021, 10(8):e017401]

Cited: 0 times

View full text PDF listing >>



Biomarkers of platelet activation and cardiovascular risk in the DAPT trial.

David D Berg, Robert W Yeh, Laura Mauri, David A Morrow, Dean J Kereiakes, Donald E Cutlip, Qi Gao, Petr Jarolim, Alan D Michelson, Andrew L Frelinger, Abby L Cange, Marc S Sabatine, Michelle L O'Donoghue,

Prolonged use of dual antiplatelet therapy (DAPT) post-percutaneous coronary intervention (PCI) has been shown to reduce the risk of major adverse cardiovascular events (MACE), but with increased bleeding. It remains unknown whether biomarkers of platelet activation may be useful for identifying patients at increased risk of MACE. The DAPT study was ... Read more >>

J Thromb Thrombolysis (Journal of thrombosis and thrombolysis)
[2021, 51(3):675-681]

Cited: 1 time

View full text PDF listing >>



Efficacy and Safety of Dapagliflozin in Men and Women With Heart Failure With Reduced Ejection Fraction: A Prespecified Analysis of the Dapagliflozin and Prevention of Adverse Outcomes in Heart Failure Trial.

Jawad H Butt, Kieran F Docherty, Mark C Petrie, Morten Schou, Mikhail N Kosiborod, Eileen O'Meara, Tzvetana Katova, Charlotta E A Ljungman, Mirta Diez, Modele O Ogunniyi, Anna Maria Langkilde, Mikaela Sjöstrand, Daniel Lindholm, Olof Bengtsson, Felipe A Martinez, Piotr Ponikowski, Marc S Sabatine, Scott D Solomon, Pardeep S Jhund, John J V McMurray, Lars Køber,

<h4>Importance</h4>Women may respond differently to certain treatments for heart failure (HF) with reduced ejection fraction (HFrEF) than men.<h4>Objective</h4>To investigate the efficacy and safety of dapagliflozin compared with placebo in men and women with HFrEF enrolled in the Dapagliflozin and Prevention of Adverse Outcomes in Heart Failure trial (DAPA-HF).<h4>Design, setting, and ... Read more >>

JAMA Cardiol (JAMA cardiology)
[2021, :]

Cited: 0 times

View full text PDF listing >>



PCSK9 Inhibition-A Tale of 2 Potential Treatment Opportunities-Reply.

Brian A Bergmark, Marc S Sabatine,

JAMA Cardiol (JAMA cardiology)
[2021, 6(4):481]

Cited: 0 times

View full text PDF listing >>



Cardiovascular, Renal, and Metabolic Outcomes of Dapagliflozin Versus Placebo in a Primary Cardiovascular Prevention Cohort: Analyses From DECLARE-TIMI 58.

Avivit Cahn, Itamar Raz, Lawrence A Leiter, Ofri Mosenzon, Sabina A Murphy, Erica L Goodrich, Ilan Yanuv, Aliza Rozenberg, Deepak L Bhatt, Darren K McGuire, John P H Wilding, Ingrid A M Gause-Nilsson, Anna Maria Langkilde, Marc S Sabatine, Stephen D Wiviott,

<h4>Objective</h4>International guidelines propose prescribing sodium-glucose cotransporter 2 (SGLT2) inhibitors to patients with type 2 diabetes (T2D) as secondary prevention in patients with established atherosclerotic cardiovascular disease (ASCVD) or for primary prevention of cardiovascular events in high-risk patients with multiple risk factors (MRF) for ASCVD. The current analyses expand on the ... Read more >>

Diabetes Care (Diabetes care)
[2021, :]

Cited: 0 times

View full text PDF listing >>



The efficacy and safety of dapagliflozin in women and men with type 2 diabetes mellitus.

Michelle L O'Donoghue, Eri T Kato, Ofri Mosenzon, Sabina A Murphy, Avivit Cahn, Marisol Herrera, Tsvetalina Tankova, Alena Šmahelová, Piera Merlini, Ingrid Gause-Nilsson, Anna Maria Langkilde, Darren K McGuire, John P H Wilding, Larry A Leiter, Deepak L Bhatt, Itamar Raz, Marc S Sabatine, Stephen D Wiviott,

<h4>Aims/hypothesis</h4>Women remain underrepresented in clinical trials and those with type 2 diabetes mellitus are at high risk for cardiovascular (CV) events. The sodium-glucose cotransporter 2 (SGLT2) inhibitor dapagliflozin reduces the risk of CV death or heart failure hospitalisations in individuals with type 2 diabetes. Here, we performed a pre-specified analysis ... Read more >>

Diabetologia (Diabetologia)
[2021, 64(6):1226-1234]

Cited: 0 times

View full text PDF listing >>



Effect of dapagliflozin on anaemia in DAPA-HF.

Kieran F Docherty, James P Curtain, Inder S Anand, Olof Bengtsson, Silvio E Inzucchi, Lars Køber, Mikhail N Kosiborod, Anna Maria Langkilde, Felipe A Martinez, Piotr Ponikowski, Marc S Sabatine, Morten Schou, Mikaela Sjöstrand, Scott D Solomon, Pardeep S Jhund, John J V McMurray, ,

<h4>Aim</h4>Anaemia is common in heart failure and associated with worse outcomes. We examined the effect of dapagliflozin on correction of anaemia in patients with heart failure (HF) and reduced ejection fraction in DAPA-HF. We also analysed the effect of dapagliflozin on outcomes, according to anaemia status at baseline.<h4>Methods and results</h4>Anaemia ... Read more >>

Eur J Heart Fail (European journal of heart failure)
[2021, :]

Cited: 0 times

View full text PDF listing >>



Time to Clinical Benefit of Dapagliflozin and Significance of Prior Heart Failure Hospitalization in Patients With Heart Failure With Reduced Ejection Fraction.

David D Berg, Pardeep S Jhund, Kieran F Docherty, Sabina A Murphy, Subodh Verma, Silvio E Inzucchi, Lars Køber, Mikhail N Kosiborod, Anna Maria Langkilde, Felipe A Martinez, Olof Bengtsson, Piotr Ponikowski, Mikaela Sjöstrand, Scott D Solomon, John J V McMurray, Marc S Sabatine,

<h4>Importance</h4>Dapagliflozin has been shown to reduce the risk of cardiovascular death or worsening heart failure (HF) in patients with chronic HF and reduced ejection fraction (HFrEF). However, clinical inertia often underlies deferred initiation of effective therapies.<h4>Objective</h4>To examine timing of onset of clinical benefit with dapagliflozin and magnitude as a function ... Read more >>

JAMA Cardiol (JAMA cardiology)
[2021, :]

Cited: 1 time

View full text PDF listing >>



Efficacy and safety of dapagliflozin according to aetiology in heart failure with reduced ejection fraction: insights from the DAPA-HF trial.

Jawad H Butt, Jose C Nicolau, Subodh Verma, Kieran F Docherty, Mark C Petrie, Silvio E Inzucchi, Morten Schou, Mikhail N Kosiborod, Anna Maria Langkilde, Felipe A Martinez, Piotr Ponikowski, Marc S Sabatine, Mikaela Sjöstrand, Scott D Solomon, Olof Bengtsson, Pardeep S Jhund, John J V McMurray, Lars Køber,

<h4>Aims</h4>We examined the efficacy and safety of dapagliflozin, compared with placebo, according to aetiology in patients with heart failure (HF) with reduced ejection fraction (HFrEF) enrolled in the Dapagliflozin And Prevention of Adverse-outcomes in Heart Failure trial (DAPA-HF).<h4>Methods and results</h4>Aetiology was investigator-reported and categorized as ischaemic or non-ischaemic. The primary ... Read more >>

Eur J Heart Fail (European journal of heart failure)
[2021, :]

Cited: 0 times

View full text PDF listing >>



Predictors, Type, and Impact of Bleeding on the Net Clinical Benefit of Long-Term Ticagrelor in Stable Patients With Prior Myocardial Infarction.

Giulia Magnani, Diego Ardissino, KyungAh Im, Andrzej Budaj, Robert F Storey, P Gabriel Steg, Deepak L Bhatt, Marc Cohen, Ton Oude Ophius, Assen Goudev, Alexander Parkhomenko, Gabriel Kamensky, Dominick J Angiolillo, José López-Sendón, Per Johanson, Eugene Braunwald, Marc S Sabatine, Marc P Bonaca,

Background Ticagrelor reduces ischemic risk but increases bleeding in patients with prior myocardial infarction. Identification of patients at lower bleeding risk is important in selecting patients who are likely to derive more favorable outcomes versus risk from this strategy. Methods and Results PEGASUS-TIMI 54 (Prevention of Cardiovascular Events in Patients ... Read more >>

J Am Heart Assoc (Journal of the American Heart Association)
[2021, 10(4):e017008]

Cited: 2 times

View full text PDF listing >>



Sex, Permanent Drug Discontinuation, and Study Retention in Clinical Trials: Insights From the TIMI trials.

Emily S Lau, Eugene Braunwald, David A Morrow, Robert P Giugliano, Elliott M Antman, C Michael Gibson, Benjamin M Scirica, Erin A Bohula, Stephen D Wiviott, Deepak L Bhatt, Marc P Bonaca, Christopher P Cannon, KyungAh Im, Jianping Guo, Marc S Sabatine, Michelle L O'Donoghue,

<h4>Background</h4>Women are underrepresented across cardiovascular clinical trials. Whether women are more likely than men to prematurely discontinue study drug or withdraw consent once enrolled in a clinical trial is unknown.<h4>Methods</h4>Eleven phase 3/4 TIMI (Thrombolysis in Myocardial Infarction) trials were included (135 879 men and 51 812 women [28%]). The association ... Read more >>

Circulation (Circulation)
[2021, 143(7):685-695]

Cited: 0 times

View full text PDF listing >>



Efficacy and Safety of PCSK9 Inhibition With Evolocumab in Reducing Cardiovascular Events in Patients With Metabolic Syndrome Receiving Statin Therapy: Secondary Analysis From the FOURIER Randomized Clinical Trial.

Prakash Deedwania, Sabina A Murphy, Andre Scheen, Jolita Badariene, Armando Lira Pineda, Narimon Honarpour, Anthony C Keech, Peter S Sever, Terje R Pedersen, Marc S Sabatine, Robert P Giugliano,

<h4>Importance</h4>The PCSK9 inhibitor evolocumab reduced low-density lipoprotein cholesterol and cardiovascular events in the FOURIER randomized clinical trial. Patients with metabolic syndrome (MetS) are at increased cardiovascular risk.<h4>Objective</h4>To investigate outcomes with evolocumab in patients with and without MetS.<h4>Design, setting, and participants</h4>The FOURIER trial randomized patients worldwide with stable atherosclerotic cardiovascular disease ... Read more >>

JAMA Cardiol (JAMA cardiology)
[2021, 6(2):139-147]

Cited: 2 times

View full text PDF listing >>



Recombinant human Lecithin-Cholesterol acyltransferase in patients with atherosclerosis: Phase 2a primary results and phase 2b design.

Marc P Bonaca, Richard T George, David A Morrow, Brian A Bergmark, Jeong-Gun Park, Liron Abuhatzira, Andrea L Vavere, Sotirios K Karathanasis, ChaoYu Jin, Dewei She, Boaz Hirshberg, Judy Hsia, Marc S Sabatine,

<h4>Background</h4>Reverse cholesterol transport (RCT) removes cholesterol and stabilizes vulnerable plaques. In addition, high-density lipoprotein (HDL) may be cardioprotective in acute MI. Lecithin-cholesterol acyltransferase (LCAT) may enhance RCT. The objective of this study was to investigate the pharmacokinetics, pharmacodynamics, and safety of multiple ascending doses of recombinant human LCAT (MEDI6012) to ... Read more >>

Eur Heart J Cardiovasc Pharmacother (European heart journal. Cardiovascular pharmacotherapy)
[2021, :]

Cited: 0 times

View full text PDF listing >>



Dapagliflozin in HFrEF Patients Treated With Mineralocorticoid Receptor Antagonists: An Analysis of DAPA-HF.

Li Shen, Søren Lund Kristensen, Olof Bengtsson, Michael Böhm, Rudolf A de Boer, Kieran F Docherty, Silvio E Inzucchi, Tzvetana Katova, Lars Køber, Mikhail N Kosiborod, Anna Maria Langkilde, Daniel Lindholm, M Felipe A Martinez, Eileen O'Meara, Jose C Nicolau, Mark C Petrie, Piotr Ponikowski, Marc S Sabatine, Morten Schou, Mikaela Sjöstrand, Scott D Solomon, Pardeep S Jhund, John J V McMurray,

<h4>Objectives</h4>The purpose of this study was to assess the efficacy and safety of dapagliflozin in patients taking or not taking an mineralocorticoid receptor antagonist (MRA) at baseline in the DAPA-HF (Dapagliflozin And Prevention of Adverse outcomes in Heart Failure) trial.<h4>Background</h4>MRAs and sodium glucose co-transporter 2 inhibitors each have diuretic activity, lower ... Read more >>

JACC Heart Fail (JACC. Heart failure)
[2021, 9(4):254-264]

Cited: 0 times

View full text PDF listing >>



Prevalence, clinical determinants and prognostic implications of coronary procedural complications of percutaneous coronary intervention in non-ST-segment elevation myocardial infarction: Insights from the contemporary multinational TAO trial.

Jeremie Abtan, Stephen D Wiviott, Emmanuel Sorbets, Batric Popovic, Yedid Elbez, Shamir R Mehta, Marc S Sabatine, Christoph Bode, Charles V Pollack, Marc Cohen, Tiziano Moccetti, Peep Laanmets, David Faxon, Andrzej Okreglicki, Gregory Ducrocq, Ph Gabriel Steg, ,

<h4>Background</h4>Few data are available on procedural complications of percutaneous coronary intervention (PCI) in the setting of acute coronary syndrome in the contemporary era.<h4>Aim</h4>We sought to describe the prevalence of procedural complications of PCI in a non-ST-segment elevation acute coronary syndrome (NSTE ACS) cohort, and to identify their clinical characteristics and ... Read more >>

Arch Cardiovasc Dis (Archives of cardiovascular diseases)
[2021, 114(3):187-196]

Cited: 0 times

View full text PDF listing >>



Sex Differences in Ischemic and Bleeding Outcomes in Patients With Non-ST-Segment-Elevation Acute Coronary Syndrome Undergoing Percutaneous Coronary Intervention: Insights From the TAO Trial.

Jean-Guillaume Dillinger, Gregory Ducrocq, Yedid Elbez, Marc Cohen, Christoph Bode, Charles Pollack, Birute Petrauskiene, Patrick Henry, Maria Dorobantu, William J French, Stephen D Wiviott, Marc S Sabatine, Shamir R Mehta, Philippe Gabriel Steg,

<h4>Background</h4>Previous studies have observed poorer outcomes in females with myocardial infarction, but older age and lower use of percutaneous coronary intervention in females are factors that potentially explain the worse outcome. This study sought to determine if female sex is an independent factor of ischemic and bleeding outcomes in non-ST-segment-elevation ... Read more >>

Circ Cardiovasc Interv (Circulation. Cardiovascular interventions)
[2021, 14(1):e009759]

Cited: 0 times

View full text PDF listing >>



Genetic Risk Score to Identify Risk of Venous Thromboembolism in Patients With Cardiometabolic Disease.

Nicholas A Marston, Giorgio E M Melloni, Yared Gurmu, Marc P Bonaca, Frederick K Kamanu, Carolina Roselli, Christina Lee, Ilaria Cavallari, Robert P Giugliano, Benjamin M Scirica, Deepak L Bhatt, Philippe Gabriel Steg, Marc Cohen, Robert F Storey, Anthony C Keech, Itamar Raz, Ofri Mosenzon, Eugene Braunwald, Steven A Lubitz, Patrick T Ellinor, Marc S Sabatine, Christian T Ruff,

<h4>Background</h4>Venous thromboembolism (VTE) is a major cause of cardiovascular morbidity and mortality and has a known genetic contribution. We tested the performance of a genetic risk score for its ability to predict VTE in 3 cohorts of patients with cardiometabolic disease.<h4>Methods</h4>We included patients from the FOURIER (Further Cardiovascular Outcomes Research ... Read more >>

Circ Genom Precis Med (Circulation. Genomic and precision medicine)
[2021, 14(1):e003006]

Cited: 0 times

View full text PDF listing >>



Letter to the editor re: 'serious adverse events and deaths in PCSK9 inhibitor trials reported on ClinicalTrials.gov: a systematic review'.

Marc S Sabatine, Robert P Giugliano, Gregory G Schwartz,

Expert Rev Clin Pharmacol (Expert review of clinical pharmacology)
[2021, 14(2):281-282]

Cited: 0 times

View full text PDF listing >>



Plasma ceramide and phospholipid-based risk score and the risk of cardiovascular death in patients after acute coronary syndrome.

Baris Gencer, David A Morrow, Eugene Braunwald, Erica L Goodrich, Mika Hilvo, Dimple Kauhanen, Marc S Sabatine, Reijo Laaksonen, Michelle L O'Donoghue,

<h4>Aims</h4>Ceramide (Cer) and phosphatidylcholine (PC) lipids are associated with pathophysiological processes in cardiovascular (CV) diseases. A previously derived and validated plasma Cer-PC risk score (CERT2) was associated with CV death risk in patients with stable disease, but its prognostic value has not been evaluated in patients early post-acute coronary syndrome ... Read more >>

Eur J Prev Cardiol (European journal of preventive cardiology)
[2020, :]

Cited: 0 times

View full text PDF listing >>



Effects of dapagliflozin in heart failure with reduced ejection fraction, and chronic obstructive pulmonary disease: an analysis of DAPA-HF.

Pooja Dewan, Kieran F Docherty, Olof Bengtsson, Rudolf A de Boer, Akshay S Desai, Jaroslaw Drozdz, Nathaniel M Hawkins, Silvio E Inzucchi, Masafumi Kitakaze, Lars Køber, Mikail N Kosiborod, Anna Maria Langkilde, Daniel Lindholm, Felipe A Martinez, Béla Merkely, Mark C Petrie, Piotr Ponikowski, Marc S Sabatine, Morten Schou, Mikaela Sjöstrand, Scott D Solomon, Subodh Verma, Pardeep S Jhund, John J V McMurray,

<h4>Aims</h4>Chronic obstructive pulmonary disease (COPD) is an important comorbidity in heart failure (HF) with reduced ejection fraction (HFrEF), associated with worse outcomes and often suboptimal treatment because of under-prescription of beta-blockers. Consequently, additional effective therapies are especially relevant in patients with COPD. The aim of this study was to examine ... Read more >>

Eur J Heart Fail (European journal of heart failure)
[2020, :]

Cited: 0 times

View full text PDF listing >>



Aspirin or P2Y12 inhibition: establishing the cornerstone of antiplatelet therapy after stenting.

Michelle L O'Donoghue, Marc S Sabatine,

Eur Heart J (European heart journal)
[2021, 42(4):320-322]

Cited: 0 times

View full text PDF listing >>



Advertisement

Disclaimer
1.0649 s